Tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma.

IF 6.6 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice Pub Date : 2025-09-11 DOI:10.1016/j.jaip.2025.09.001

Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, Anne-Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen, Roxana Vijdea, Anna von Bülow, Niels Steen Krogh, Ole Hilberg, Charlotte Suppli Ulrik, Celeste Porsbjerg

{"title":"Tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma.","authors":"Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, Anne-Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Claus Rikard Johnsen, Barbara Bonnesen, Roxana Vijdea, Anna von Bülow, Niels Steen Krogh, Ole Hilberg, Charlotte Suppli Ulrik, Celeste Porsbjerg","doi":"10.1016/j.jaip.2025.09.001","DOIUrl":null,"url":null,"abstract":"Background: Tezepelumab holds significant potential in severe asthma owing to its upstream target in the inflammatory cascade and could be an appropriate choice of biologic for different patient groups.Objectives: We aimed to characterise the patients prescribed tezepelumab during the first two years of the drug being available and its illuminate efficacy in a nationwide Danish cohort of patients with severe asthma.Methods: In this prospective observational study, we used data from the Danish Severe Asthma Register (DSAR). We categorised patients according to their previous biological treatment as either Biologic-naive or Switchers, compared baseline charecteristics and investigated efficacy after 12 months of treatment.Results: Of the 273 patients initiated on tezepelumab, 171 (63 %) were switchers. Biologic-naive patients had a median blood eosinophil count of 0.20 cells x 109/L and fractional exhaled nitric oxide (FeNO) of 17 ppb. 172 patients were included in efficacy analyses and after 12 months of treatment, both biologic-naive patients and switchers showed significant improvements in maintenance oral corticosteroid use, symptoms and reduced exacerbations by 69 %. The majority of patients in both groups achieved a clinical response to treatment, however, a larger proportion of biologic-naïve patients achieved clinical remission (35 % vs 15 %, p=0.01).Conclusion: Most patients initiating tezepelumab in real-life clinical practice were switchers, and the biologic-naive patients initiated had relatively low type-2 inflammatory biomarkers, highlighting the complexity of patients on tezepelumab. However, both groups showed a clinical response rate to treatment, comparable to that seen in Danish patients initiated on other biologics.","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaip.2025.09.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tezepelumab holds significant potential in severe asthma owing to its upstream target in the inflammatory cascade and could be an appropriate choice of biologic for different patient groups.

Objectives: We aimed to characterise the patients prescribed tezepelumab during the first two years of the drug being available and its illuminate efficacy in a nationwide Danish cohort of patients with severe asthma.

Methods: In this prospective observational study, we used data from the Danish Severe Asthma Register (DSAR). We categorised patients according to their previous biological treatment as either Biologic-naive or Switchers, compared baseline charecteristics and investigated efficacy after 12 months of treatment.

Results: Of the 273 patients initiated on tezepelumab, 171 (63 %) were switchers. Biologic-naive patients had a median blood eosinophil count of 0.20 cells x 10⁹/L and fractional exhaled nitric oxide (FeNO) of 17 ppb. 172 patients were included in efficacy analyses and after 12 months of treatment, both biologic-naive patients and switchers showed significant improvements in maintenance oral corticosteroid use, symptoms and reduced exacerbations by 69 %. The majority of patients in both groups achieved a clinical response to treatment, however, a larger proportion of biologic-naïve patients achieved clinical remission (35 % vs 15 %, p=0.01).

Conclusion: Most patients initiating tezepelumab in real-life clinical practice were switchers, and the biologic-naive patients initiated had relatively low type-2 inflammatory biomarkers, highlighting the complexity of patients on tezepelumab. However, both groups showed a clinical response rate to treatment, comparable to that seen in Danish patients initiated on other biologics.

查看原文本刊更多论文

Tezepelumab在现实生活中的应用：在丹麦全国范围内的严重哮喘患者队列中开始的患者特征和疗效。

背景：Tezepelumab由于其炎症级联的上游靶点，在严重哮喘中具有显著的潜力，可能是不同患者群体的合适生物制剂选择。目的：我们的目的是描述tezepelumab在药物可用的前两年处方患者及其在丹麦全国严重哮喘患者队列中的疗效。方法：在这项前瞻性观察性研究中，我们使用了丹麦严重哮喘登记（DSAR）的数据。我们根据患者先前的生物治疗将其分类为生物初始治疗或转换治疗，比较基线特征并调查治疗12个月后的疗效。结果：在273例开始使用tezepelumab的患者中，171例（63%）是切换者。未接受生物学治疗的患者血嗜酸性粒细胞中位数为0.20 × 109/L，呼出一氧化氮（FeNO）分数为17 ppb。172例患者纳入疗效分析，治疗12个月后，生物初始患者和转换者在维持口服皮质类固醇使用、症状和恶化减少69%方面均有显着改善。两组中大多数患者对治疗均有临床反应，但更大比例的biologic-naïve患者获得临床缓解（35% vs 15%, p=0.01）。结论：在现实临床实践中，大多数开始使用tezepelumab的患者是切换者，并且生物初始患者的2型炎症生物标志物相对较低，突出了tezepelumab患者的复杂性。然而，两组均显示出治疗的临床反应率，与开始使用其他生物制剂的丹麦患者相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Allergy and Clinical Immunology-In Practice ALLERGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

11.10

自引率

9.60%

发文量

683

审稿时长

50 days

期刊介绍： JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases. This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders. The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.